MedCity News October 10, 2023
Merith Basey, executive director of Patients For Affordable Drugs, believes the Medicare price negotiation program is here to stay, no matter who is president and no matter how many Big Pharma players file lawsuits. Her reasoning? Every other high income nation has been negotiating prices with drugmakers for years, and the program is widely popular in the U.S. among pretty much everyone who isn’t a pharma company, she said during a session at Engage at HLTH.
After much anticipation and a bevy of (ongoing) lawsuits, the U.S. government is finally beginning to negotiate drug prices with pharmaceutical companies — the White House announced last week that all 10 drugmakers whose drugs were selected for the first cycle of the Medicare...
Today's Sponsors
Today's Sponsor